glioma - search results
If you're not happy with the results, please do another search
Blocking the protein ZMYND8 could lead to more effective radiotherapy for mutated forms of the brain cancer glioma, according to a new study.
Glioma brain cancer cells with mutated ATRX protein can be better targeted with the use of radiation sensitizers to help ensure cancer cell destruction during radiotherapy, according to University of Michigan researchers.
The research team identified a blood growth factor secreted by tumors harboring the mutation—one already used by doctors to stimulate the production of white blood cells and reduce the risk of infection in patients receiving chemotherapy—that holds promise for making treatments against gliomas more effective.
Researchers in the department of neurosurgery at Massachusetts General Hospital found that a novel blood test they pioneered could accurately detect and monitor two mutations of the genes TERT, C228T, and C250T over time.
Research from the Spanish National Cancer Research Center (CNIO) and the Hong Kong University of Science and Technology (HKUST) shows that a subset of patients acquires a specific genetic alteration that can evade treatment from a combination of chemotherapy and radiotherapy.
It is known that the majority of glioblastomas have mutations in the EGFR gene, but until now it has not been totally clear what causes the cancer to start and what role mutations in other genes, such as those that normally suppress tumor formation, play in driving this cancer.
In the first analysis, researchers discovered highly variable and patient-specific genomic alterations in patients with diffuse gliomas. They determined that mutations are largely driven early in glioma development and diverge rapidly thereafter.
Researchers have utilized genomic analyses in dogs to identify genes that have a role in brain tumorigenesis for both dogs and human.
CureSearch for Children’s Cancer announced on Wednesday that it will collaborate with leading research institutions and corporate sponsors to launch a health economics study on the benefits of providing molecular testing for children with cancer.
Inhibiting DHODH in medulloblastoma of the MYC-amplified subtype stopped cancer growth but did not interfere with surrounding normal neural stem cells.